Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Rhea-AI Summary

Nuvation Bio (NYSE: NUVB) reported pooled long-term data from TRUST-I and TRUST-II showing durable responses with IBTROZI (taletrectinib) in ROS1+ NSCLC. In TKI-naïve patients cORR was 89.8%, median DOR 49.7 months and median PFS 46.1 months. TKI-pretreated patients showed cORR 55.8% and median PFS 9.7 months.

The pooled safety analysis found a manageable profile, low rates of neurologic events, 8.5% discontinuations for TEAEs, strong intracranial activity, and concurrent TRUST-I results published in Journal of Clinical Oncology.

Positive

• cORR 89.8% in TKI-naïve ROS1+ patients
• Median DOR 49.7 months in TKI-naïve cohort
• Median PFS 46.1 months in TKI-naïve cohort
• Intracranial response 76.5% in TKI-naïve patients with brain metastases
• FDA approval in June 2025 and EMA MAA validated for review

Negative

• TKI-pretreated cORR only 55.8% (n=113)
• TKI-pretreated median PFS 9.7 months, median OS 29.8 months
• Treatment discontinuations due to TEAEs at 8.5%

News Market Reaction – NUVB

+0.20%

1 alert

+0.20% Session close to close

$1.78B Market Cap

1.33K Volume

In the Apr 22 session, NUVB gained 0.20%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reinforces IBTROZI’s role in ROS1+ NSCLC with a cORR of 89.8%, mDOR of 49.7 months...

Analysis

This announcement reinforces IBTROZI’s role in ROS1+ NSCLC with a cORR of 89.8%, mDOR of 49.7 months, and strong intracranial activity in TKI‑naïve and pretreated patients. It builds directly on earlier AACR‑preview and EMA‑validation news, now backed by longer-term follow‑up and publication in the Journal of Clinical Oncology. Investors may watch how these outcomes support global adoption alongside previously reported cash levels, losses, and expanding collaborations.

Key Figures

cORR TKI-naïve: 89.8% mDOR TKI-naïve: 49.7 months mPFS TKI-naïve: 46.1 months +5 more

8 metrics

cORR TKI-naïve 89.8% TRUST-I/II pooled ROS1+ NSCLC, TKI-naïve patients

mDOR TKI-naïve 49.7 months TRUST-I/II pooled ROS1+ NSCLC, TKI-naïve patients

mPFS TKI-naïve 46.1 months TRUST-I/II pooled ROS1+ NSCLC, TKI-naïve patients

Intracranial response 76.5% (n=17) TKI-naïve ROS1+ NSCLC patients with brain metastases

cORR TKI-pretreated 55.8% TRUST-I/II pooled ROS1+ NSCLC, TKI-pretreated patients

mDOR TKI-pretreated 16.6 months TRUST-I/II pooled ROS1+ NSCLC, TKI-pretreated patients

mPFS TKI-pretreated 9.7 months TRUST-I/II pooled ROS1+ NSCLC, TKI-pretreated patients

Intracranial response 65.6% (n=32) TKI-pretreated ROS1+ NSCLC patients with brain metastases

Historical Context

5 past events · Latest: Apr 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 01	Pipeline acquisition	Positive	+5.1%	Acquired Japan rights to safusidenib, securing global development and commercialization.
Mar 26	Regulatory milestone	Positive	-3.9%	EMA validated taletrectinib MAA for advanced ROS1+ NSCLC under standard review.
Mar 17	Clinical data preview	Positive	-2.7%	Announced upcoming AACR 2026 presentations of pivotal IBTROZI data in ROS1+ NSCLC.
Mar 02	Earnings and update	Negative	-25.3%	Reported Q4 and FY 2025 results with sizeable net losses despite strong cash balance.
Feb 25	Investor outreach	Neutral	-1.4%	Management scheduled March 2026 investor conference appearances and webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

High-impact news, including clinical and regulatory updates, has often met with mixed or negative next‑day reactions, particularly around financial results and major taletrectinib milestones.

Recent Company History

Over the past few months, Nuvation Bio has advanced both its pipeline and commercial footprint. An April 1, 2026 deal expanded safusidenib rights and Phase 3 trial reach. Earlier, the EMA validated a taletrectinib MAA and the company previewed pivotal IBTROZI data for AACR 2026. Financial results on March 2, 2026 highlighted substantial cash but also sizable net losses, while management maintained visibility through investor conferences. Today’s detailed, longer‑term IBTROZI outcomes build directly on the AACR preview and EMA submission narrative.

Key Terms

non-small cell lung cancer, progression-free survival, objective response rate, intracranial response rate, +4 more

8 terms

non-small cell lung cancer medical

"patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)."

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

progression-free survival medical

"a median duration of response (mDOR) of 49.7 months and a median progression-free survival (mPFS) of 46.1 months."

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

objective response rate medical

"demonstrated a confirmed objective response rate (cORR) of 89.8%, a median duration of response"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

intracranial response rate medical

"and an intracranial response rate of 76.5% in patients with brain metastases (n=17)."

The intracranial response rate measures the share of patients whose brain tumors shrink or disappear on imaging after a treatment, typically within a defined time frame and by agreed criteria. For investors, it is a direct signal of how well a therapy works in the brain — like the batting average for a player — and can influence a drug’s commercial potential, regulatory prospects, and competitive standing in markets where controlling brain disease is important.

epithelial to mesenchymal transition medical

"reduced the expression of key markers associated with the epithelial to mesenchymal transition pathway."

Epithelial to mesenchymal transition is a biological process where normally stationary, tightly connected cells change into a more mobile, flexible state that can move through tissue. For investors, it matters because this change underlies tumor spread, treatment resistance, and some chronic scarring conditions, so drugs or diagnostics that detect or block this shift can alter the commercial value and risk of healthcare assets. Think of bricks in a wall turning into roaming repair crews.

tropomyosin receptor kinase B (TRKB) medical

"based on its tropomyosin receptor kinase B (TRKB) inhibition profile."

Tropomyosin receptor kinase B (TrkB) is a protein on the surface of certain cells that acts like a lock and key for growth signals (notably BDNF), turning on internal programs that control nerve cell survival, growth and communication. It matters to investors because drugs that activate or block TrkB can alter the course of neurological, psychiatric or some cancer conditions, so progress or failure in TrkB-targeted research and trials often moves biotech valuations the way a key component affects an entire product's value.

Marketing Authorisation Application (MAA) regulatory

"the Marketing Authorisation Application (MAA) for taletrectinib was validated by the European Medicines Agency"

An marketing authorisation application is a formal request submitted to a health regulator asking for permission to sell a new medicine or medical product in a given market. For investors it matters because approval is the regulatory ‘green light’ that allows commercial sales and revenue, while delays, additional requirements, or rejection create uncertainty about timing, costs and a product’s market potential.

TRKB-sparing agents medical

"The data also suggested that TRKB-sparing agents may not reduce the migration of TRKB expressing lung cancer cells"

TrkB-sparing agents are drugs designed to avoid activating or blocking the TrkB receptor, a protein on nerve cells that responds to growth signals. Investors care because avoiding TrkB can reduce the risk of neurological side effects and regulatory hurdles, making a drug safer and more likely to reach market; think of it like a key engineered to open one lock without jiggling nearby locks that could cause problems.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients

IBTROZI also demonstrated a high overall response rate in TKI-naïve patients at 89.8%

Long-term pooled data highlighted in oral and poster presentations at AACR, and TRUST-I data simultaneously published in the Journal of Clinical Oncology, reinforce IBTROZI's manageable safety profile, with low rates of neurologic side effects and no new safety signals

IBTROZI demonstrated robust CNS activity, with an intracranial response rate of 76.5% in TKI-naïve patients and 65.6% in TKI-pretreated patients with brain metastases

Preclinical data presented at AACR showed taletrectinib's potential for suppressing TRKB-mediated lung cancer cell migration

NEW YORK, April 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI^® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The updated efficacy and safety results for both TKI-naïve and TKI-pretreated patients were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in oral and poster presentations. The long-term pooled results in TKI-naïve patients demonstrated a confirmed objective response rate (cORR) of 89.8%, a median duration of response (mDOR) of 49.7 months and a median progression-free survival (mPFS) of 46.1 months. Updated results from the TRUST-I study were also simultaneously published in the Journal of Clinical Oncology, demonstrating robust ORR, mDOR and mPFS in TKI-naïve patients, with a median follow up of 51 months.

"Achieving durable responses is a primary goal in treating ROS1-positive lung cancer. These extensive follow-up data with this next-generation ROS1 inhibitor show high rates of responses that last more than four years for many patients, and a median progression-free survival that's nearly just as long," stated Lyudmila Bazhenova, M.D., Medical Oncologist at UC San Diego Health, Professor of Medicine at University of California San Diego School of Medicine and investigator for the TRUST-II study. "Critically, the data demonstrated robust intracranial activity without the significant central nervous system toxicities that often limit the long-term use of other brain-penetrant therapies, and a favorable safety profile that allowed patients to stay on treatment and continue to benefit."

The new pooled analysis presented at AACR demonstrated robust efficacy with IBTROZI for both TKI-naïve and TKI-pretreated patients in TRUST-I and TRUST-II.

• For TKI-naïve patients (n=157): the analysis showed a cORR of 89.8%, a median DOR of 49.7 months, a median PFS of 46.1 months and an intracranial response rate of 76.5% in patients with brain metastases (n=17). Median OS was not yet reached.
• For TKI-pretreated patients (n=113): the analysis showed a cORR of 55.8%, a median DOR of 16.6 months, a median PFS of 9.7 months and an intracranial response rate of 65.6% in patients with brain metastases (n=32). Median OS was 29.8 months. Notably, 98% of TKI-pretreated patients (111/113) enrolled following progressive disease on entrectinib or crizotinib. The remaining two patients were enrolled following intolerance to a prior TKI. 

A pooled safety analysis demonstrated a favorable and manageable safety profile for IBTROZI, consistent with its prescribing information. Adverse events (AEs) of clinical interest (diarrhea, nausea, vomiting and dizziness) were generally low-grade and resolved quickly. Treatment discontinuations due to treatment-emergent AEs (TEAEs) were low (8.5%). No new safety signals were identified with the longer follow-up.

In another poster session at AACR, new preclinical data showed that taletrectinib inhibited the migration of lung cancer cells, suggesting the ability of taletrectinib to reduce the invasive capacity of lung cancer cells based on its tropomyosin receptor kinase B (TRKB) inhibition profile. In mechanistic studies, taletrectinib reduced the expression of key markers associated with the epithelial to mesenchymal transition pathway. The data also suggested that TRKB-sparing agents may not reduce the migration of TRKB expressing lung cancer cells and may lack the potential CNS-protective effects of TRKB inhibition.

"Our objective was to redefine the standard of care for advanced ROS1-positive NSCLC, and we believe IBTROZI is delivering on that promise," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "In these updated long-term clinical data presented at AACR and published in the prestigious Journal of Clinical Oncology, IBTROZI demonstrated remarkable durability, underscored by the long mDOR and mPFS seen in ROS1+ TKI-naïve patients. And new preclinical data suggest that taletrectinib inhibits critical pathways that can lead to metastasis. When you combine these benefits with its favorable safety profile, you have a treatment that we believe addresses the disease from all angles."

Nuvation Bio announced in June 2025 that the U.S. Food and Drug Administration (FDA) approved IBTROZI for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. IBTROZI is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON^®. Additionally, Nuvation Bio, along with its partner Eisai, announced in March 2026 that the Marketing Authorisation Application (MAA) for taletrectinib was validated by the European Medicines Agency and accepted for full approval consideration with a standard review timeline.

To review the publications, visit the Publications page of the Nuvation Bio website.

About ROS1+ NSCLC
Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.

About IBTROZI
IBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 

About the TRUST Clinical Program
The TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of IBTROZI. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating IBTROZI for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating IBTROZI for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating IBTROZI versus crizotinib in 194 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs. 

U.S. Indication
IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC).

IMPORTANT SAFETY INFORMATION FOR IBTROZI^® (taletrectinib) 

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).

Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.

Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).

ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.

QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.

In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.

Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.

Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.

Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).

Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.

Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.

Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.

ADVERSE REACTIONS

Among patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).

The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).

DRUG INTERACTIONS

• Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.
• Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI.

OTHER CONSIDERATIONS

• Pregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.
• Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.
• Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.
• Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.
• Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation.

Please see accompanying full Prescribing Information.

About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding IBTROZI'S therapeutic potential, IBTROZI's potential to redefine standard of care for advanced ROS1+ NSCLC, and whether TRKB inhibition has CNS-protective effects in lung cancer. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Media and Investor Contacts

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-announces-ibtrozi-taletrectinib-showed-highly-durable-responses-in-longer-term-follow-up-data-from-pivotal-studies-presented-at-aacr-2026-302749252.html

SOURCE Nuvation Bio Inc.

FAQ

What were the key efficacy results for IBTROZI (taletrectinib) in TKI-naïve patients reported April 21, 2026 (NUVB)?

The TKI-naïve group showed a cORR of 89.8%, median DOR 49.7 months and median PFS 46.1 months. According to the company, these figures come from pooled TRUST-I and TRUST-II long-term follow-up presented at AACR 2026.

How did IBTROZI perform intracranially in ROS1+ NSCLC patients with brain metastases (NUVB)?

IBTROZI showed high intracranial activity, with a 76.5% response in TKI-naïve and 65.6% in TKI-pretreated patients. According to the company, these rates were reported in the pooled TRUST-I/II analysis presented at AACR 2026.

What safety and discontinuation rates were reported for IBTROZI in the AACR 2026 pooled analysis (NUVB)?

The pooled safety analysis described a manageable profile and low serious neurologic events, with 8.5% discontinuations for treatment-emergent adverse events. According to the company, no new safety signals emerged with longer follow-up.

How did IBTROZI perform in TKI-pretreated ROS1+ NSCLC patients in the April 21, 2026 update (NUVB)?

In TKI-pretreated patients, cORR was 55.8%, median DOR 16.6 months, and median PFS 9.7 months. According to the company, most pretreated patients previously progressed on entrectinib or crizotinib.

What regulatory milestones for taletrectinib (IBTROZI) were noted by NUVB in April 2026?

NUVB noted U.S. FDA approval in June 2025 and that the EMA validated the MAA for standard review in March 2026. According to the company, IBTROZI is also approved and marketed in Japan and China.